Exploiting innate nucleic acid receptor pathways to enhance immunotherapy in SCLC (C07*)

利用先天核酸受体途径增强 SCLC 的免疫治疗 (C07*)

• 批准号: 524434524
• 金额: --
• 依托单位: Abteilung Translationale Genomik
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/524434524?language=en
• 关键词: Exploiting; innate; nucleic; acid; receptor

J. Brägelmann and his team will address a new opportunity in SCLC, direct activation of the immune system for mounting a therapeutically relevant immune response. They have found that activation of innate nucleic acid receptors (NARs) causes activation and cytokine secretion. Moving forward, they will now characterize in-depth the signaling responses elicited by NAR activation in SCLC. They will then seek to determine, whether NAR activation results in meaningful cellular activation and cytotoxicity elicited by T and NK cells in co-culture experiments. In a complementary approach, the team will employ a newly generated RPM-Cas9 mouse model to assess immune recognition and response in this aggressive immunocompetent mouse model and to determine the therapeutic potential of combined NAR activation and immunotherapy.

J.BräGelmann和他的团队将探讨小细胞肺癌的一个新机会，即直接激活免疫系统，以启动与治疗相关的免疫反应。他们发现，先天核酸受体(NAR)的激活会导致激活和细胞因子的分泌。展望未来，他们现在将深入描述小细胞肺癌中NAR激活所引发的信号反应。然后，他们将寻求确定，在共培养实验中，NAR激活是否导致T和NK细胞引起的有意义的细胞激活和细胞毒性。在一种补充方法中，该团队将使用新产生的RPM-Cas9小鼠模型来评估这种具有积极免疫能力的小鼠模型中的免疫识别和反应，并确定NAR激活和免疫治疗相结合的治疗潜力。